SALL4 and its clinical application value in nongerm cell tumors

Abstract

Abstract: Sallike 4 (SALL4) plays an important role in promoting the cellular proliferation and maintaining the pluripotency of embryonic stem cells and tumor cells. In fully differentiated cells, the expression of SALL4 is silenced or downregulated. However, the expression of SALL4 is found to be restored or upregulated in a variety of nongerm cell tumors. Besides, the expression of SALL4 is often associated with disease progression, treatment effect and prognosis. Therefore, examining the expression level of SALL4 will be of great importance in the diagnosis of disease and monitoring the disease progression for nongerm cell tumors.

Key words: Neoplasms, Diagnosis, Tumor markers, biological, Sallike 4

CHEN Yuan-Yuan, YE Yuan-Yuan, XU Feng, LI Zhi-Zhen, LIU Ying-Bin, HAN Bao-San. SALL4 and its clinical application value in nongerm cell tumors[J]. Journal of International Oncology, 2016, 43(2): 155-.

References

1］ Tanimura N, Saito M, Ebisuya M, et al. Stemnessrelated factor Sall4 interacts with transcription factors Oct3/4 and Sox2 and occupies OctSox elements in mouse embryonic stem cells［J］. J Biol Chem, 2013, 288(7): 50275038. DOI:10.1074/jbc.M112.411173. ［2］ Yong KJ, Gao C, Lim JS, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma［J］. N Engl J Med, 2013, 368(24): 22662276. DOI:10.1056/NEJMoa1300297. ［3］ Zhang L, Yan Y, Jiang Y, et al. The expression of SALL4 in patients with gliomas: high level of SALL4 expression is correlated with poor outcome［J］. J Neurooncol, 2015, 121(2): 261268. DOI:10.1007/s1106001416464. ［4］ Han SX, Wang JL, Guo XJ, et al. Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma［J］. J Immunol Res, 2014, 2014: 262385. DOI:10.1155/2014/262385. ［5］ Zeng SS, Yamashita T, Kondo M, et al. The transcription factor SALL4 regulates stemness of EpCAMpositive hepatocellular carcinoma［J］. J Hepatol, 2014, 60(1): 127134. DOI:10.1016/j.jhep.2013.08.024. ［6］ Forghanifard MM, Ardalan Khales S, JavdaniMallak A, et al. Stemness state regulators SALL4 and SOX2 are involved in progression and invasiveness of esophageal squamous cell carcinoma［J］. Med Oncol, 2014, 31(4): 922. DOI:10.1007/s1203201409227. ［7］ Cao D, Humphrey PA, Allan RW. SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors［J］. Cancer, 2009, 115(12): 26402651. DOI:10.1002/cncr.24308. ［8］ Vasiljevic A, Szathmari A, Champier J, et al. Histopathology of pineal germ cell tumors［J］. Neurochirurgie, 2015, 61(2/3): 130137. DOI:10.1016/j.neuchi.2013.06.006. ［9］ Trinh DT, Shibata K, Hirosawa T, et al. Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican3 in malignant germ cell tumors of the ovary［J］. J Obstet Gynaecol Res, 2012, 38(5): 841848. DOI:10.1111/j.14470756.2011.01798.x. ［10］ Bai S, Wei S, Ziober A, et al. SALL4 and SF1 are sensitive and specific markers for distinguishing granulosa cell tumors from yolk sac tumors［J］. Int J Surg Pathol, 2013, 21(2): 121125. DOI:10.1177/1066896912454567. ［11］ Cao D, Li J, Guo CC, et al. SALL4 is a novel diagnostic marker for testicular germ cell tumors［J］. Am J Surg Pathol, 2009, 33(7): 10651077. DOI:10.1097/PAS.0b013e3181a13eef. ［12］ Camparo P, Comperat EM. SALL4 is a useful marker in the diagnostic workup of germ cell tumors in extratesticular locations［J］. Virchows Arch, 2013, 462(3): 337341. DOI:10.1007/s0042801213535. ［13］ Yang F, Yao Y, Jiang Y, et al. Sumoylation is important for stability, subcellular localization, and transcriptional activity of SALL4, an essential stem cell transcription factor［J］. J Biol Chem, 2012, 287(46): 3860038608. DOI:10.1074/jbc.M112.391441. ［14］ Yang J, Corsello TR, Ma Y. Stem cell gene SALL4 suppresses transcription through recruitment of DNA methyltransferases［J］. J Biol Chem, 2012, 287(3): 19962005. DOI:10.1074/jbc.M111.308734. ［15］ Rao S, Zhen S, Roumiantsev S, et al. Differential roles of Sall4 isoforms in embryonic stem cell pluripotency［J］. Mol Cell Biol, 2010, 30(22): 53645380. DOI:10.1128/MCB.0041910. ［16］ Ardalan Khales S, Abbaszadegan MR, Abdollahi A, et al. SALL4 as a new biomarker for early colorectal cancers［J］. J Cancer Res Clin Oncol, 2015, 141(2): 229235. DOI:10.1007/s004320141808y. ［17］ Forghanifard MM, Moghbeli M, Raeisossadati R, et al. Role of SALL4 in the progression and metastasis of colorectal cancer［J］. J Biomed Sci, 2013, 20: 6. DOI:10.1186/14230127206. ［18］ Kobayashi D, Kuribayashi K, Tanaka M, et al. Overexpression of SALL4 in lung cancer and its importance in cell proliferation［J］. Oncol Rep, 2011, 26(4): 965970. DOI:10.3892/or.2011.1374. ［19］ Kobayashi D, Kuribayshi K, Tanaka M, et al. SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer［J］. Int J Oncol, 2011, 38(4): 933939. DOI:10.3892/ijo.2011.929. ［20］ Deisch J, Raisanen J, Rakheja D. Immunohistochemical expression of embryonic stem cell markers in malignant rhabdoid tumors［J］. Pediatr Dev Pathol, 2011, 14(5): 353359. DOI:10.2350/10090902OA.1. ［21］ Venneti S, Le P, Martinez D, et al. Malignant rhabdoid tumors Express stem cell factors, which Relate to the expression of EZH2 and Id proteins［J］. Am J Surg Pathol, 2011, 35(10): 14631472. DOI:10.1097/PAS.0b013e318224d2cd. ［22］ Yoshida A, Asano N, Kawai A, et al. Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas［J］. Histopathology, 2015, 66(2): 252261. DOI:10.1111/his.12460. ［23］ Ushiku T, Shinozaki A, Shibahara J, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma［J］. Am J Surg Pathol, 2010, 34(4): 533540. DOI:10.1097/PAS.0b013e3181d1dcdd. ［24］ Ikeda H, Sato Y, Yoneda N, et al. αFetoproteinproducing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression［J］. Hum Pathol, 2012, 43(11): 19551963. DOI:10.1016/j.humpath.2011.11.022. ［25］ Oikawa T, Kamiya A, Zeniya M, et al. Sallike protein 4 (SALL4), a stem cell biomarker in liver cancers［J］. Hepatology, 2013, 57(4): 14691483. DOI:10.1002/hep.26159. ［26］ GonzalezRoibon N, Katz B, Chaux A, et al. Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors［J］. Hum Pathol, 2013, 44(7): 12931299. DOI:10.1016/j.humpath.2012.10.017. ［27］ Liu TC, Vachharajani N, Chapman WC, et al. SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases［J］. Am J Surg Pathol, 2014, 38(7): 966972. DOI:10.1097/PAS.0000000000000218. ［28］ Momenzadeh D, Rahmanzadeh S, RezaeiTavirani M, et al. ZNF797 plays an oncogenic role in gastric cancer［J］. Genet Mol Res, 2014, 13(4): 84218427. DOI:10.4238/2014.October.20.18. ［29］ Jeong HW, Cui W, Yang Y, et al. SALL4, a stem cell factor, affects the side population by regulation of the ATPbinding cassette drug transport genes［J］. PLoS One, 2011, 6(4): e18372. DOI:10.1371/journal.pone.0018372. ［30］ Yanagihara N, Kobayashi D, Kuribayashi K, et al. Significance of SALL4 as a drug?resistant factor in lung cancer［J］. Int J Oncol, 2015, 46(4): 15271534. DOI:10.3892/ijo.2015.2866.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.